Our study extends these findings by demonstrating that within diabetic patients, treatment modality (insulin vs. oral agents) showed no association with MRS outcomes (adjusted β: 0.15, 95% CI: −0.2 to 0.5; p = 0.41) after controlling for stroke severity, age, and comorbidities. This evidence concerns the gene INS and stroke disorder.